The Delhi High Court has recently instructed both the Centre and the Delhi government to submit reports on the current stock of Antihemophilic Factor injections, which are essential for treating haemophilia, a rare genetic disorder.
The court also directed the governments to provide updates on the supply chain system in place for hospitals under their jurisdiction.
In an order passed on November 28, 2024, Justice Sanjeev Narula directed the authorities to file their status reports within the next 10 days. The case has been scheduled for further hearing on December 12, 2024.
“The respondents are directed to file status reports regarding the stock of AHF injections and the existing supply chain system for all hospitals under their administration. These reports should be submitted within ten days,” the court stated in its order.
The petition was filed by individuals suffering from haemophilia, who expressed concern over the insufficient availability of AHF injections in government hospitals.
The petitioners noted that while the injections are provided in these hospitals, stock shortages frequently occur, jeopardizing their health and well-being.
The petitioners requested that both the Centre and the Delhi government closely monitor the supply chain of AHF injections to ensure uninterrupted availability.
They also urged the authorities to devise contingency plans to manage potential shortages of this life-saving medication.
The court’s intervention highlights the critical need for consistent access to treatment for haemophilia patients, who rely on these injections to manage their condition and prevent serious health complications.
